TRDA ENTRADA THERAPEUTICS INC

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA. The fireside chat will be held on Wednesday, June 14, 2023 at 10:40 a.m. Pacific Time/1:40 p.m. Eastern Time.

A live webcast will be available on the Investor Relations section of the Company’s website at . A replay will be available on the Entrada website for 90 days following the event.

About Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).

For more information about Entrada, please visit our website, , and follow us on  and .

Investor and Media Contact

Karla MacDonald

Chief Corporate Affairs Officer



EN
06/06/2023

Underlying

TRDAENTRADA THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENTRADA THERAPEUTICS INC

 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Entrada Therapeutics Reports First Quarter 2025 Financial Results – Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – – Company remains on track to initiate ELEVATE-44-201 and ELEVATE-45-201 in Q2 and Q3 2025, respectively – – Cash runway expected into Q2 2027 with $383 million in cash, cash equivalents and marketable securities as of March 31, 2025 – BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) tod...

May 8, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Receives Authorization in the United Kingdom to I...

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping – Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing –  – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada T...

March 24, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financi...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results – Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – – Received MHRA authorization to initiate ELEVATE-44-201 in the U.K. – – Submitted regulatory filings to support global clinical studies for ENTR-601-44 in the EU, and ENTR-601-45 in the U.K. and EU – – Cash runway expected into Q2 2027 with $420 million in cash, cash equivalents and marketable securities as of December 31, 2024 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today r...

February 27, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-60...

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 – Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeu...

February 24, 2025 1 EN
 PRESS RELEASE
Free
TRDA ENTRADA THERAPE...

Entrada Therapeutics Receives Authorization in the United Kingdom to I...

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy – Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom’s Medicines and Healthcare Product...

February 3, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch